LONDON--(BUSINESS WIRE)--Lightlake Therapeutics Inc. (OTCBB: LLTP) (the “Company” or “Lightlake”), an early stage biopharmaceutical company using its expertise of opioid antagonists to develop modern addiction treatments, announced today that it will conduct Phase II trials at King’s College London on an opioid antagonist-based nasal spray treatment for Bulimia Nervosa.
Bulimia Nervosa is a condition affecting approximately 5 million people in the US today, with only about 50% of these patients finding successful treatment options. Lightlake—which is currently performing Phase II trials in Helsinki, Finland on an opioid antagonist-based nasal spray treatment for Binge Eating Disorder—is confident that it can apply the same science to develop a solution for Bulimia Nervosa. Moreover, in partnering with King’s College London, which has an internationally recognized eating disorder unit, to work on a trial that will involve the use of an opioid antagonist nasal spray for the treatment of Bulimia Nervosa, Lightlake believes that it has considerably strengthened the Company’s already distinguished research and development team.
Dr. Roger Crystal, Chief Executive Officer of Lightlake, commented, “We are very pleased to be working with King’s and to have two remarkable people from the institution sponsoring our Phase II trials. Professor Janet Treasure, head of the Eating Disorders Unit at the South London and Maudsley NHS Trust and the author of several well-regarded books on eating disorders, and Professor Ulrike Schmidt, a consultant psychiatrist for the Eating Disorders Service and a fellow of the Academy for Eating Disorders, will be tremendous guides for our Phase II trials. It is an absolute privilege to work with them and King’s in general, and we look forward to coming to the institution early next year to test a product that has the potential to improve the lives of so many people.”
About Lightlake Therapeutics, Inc.
Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients with Bulimia Nervosa as well as those who are obese or overweight as a result of Binge Eating Disorder. Lightlake also holds various patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.
Safe Harbor
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.